DSIP dosage: why there is no validated protocol

Searching for a “DSIP dosage” turns up confident-looking charts — so many micrograms, so many times a week, taken before bed. The honest starting point is that those numbers have no validated foundation. DSIP (delta sleep-inducing peptide) was never approved as a drug, no modern controlled trial has fixed a dose, and the molecule’s own biology is still unsettled.^[5] What follows is not a protocol; it is an account of the few doses real studies actually used, why they don’t translate into consumer guidance, and what the online figures really are. For the full evidence picture, start with the DSIP evidence monograph.

There is no approved DSIP and no validated dose

Most peptide dosage questions at least have an anchor — an approved label, a dose-finding study, a manufacturer’s instructions. DSIP has none of these. It is not an approved medicine in the United States or other major markets, so there is no sanctioned dose, no titration schedule, and no package insert. A 2006 review in the Journal of Neurochemistry went further still, concluding that DSIP’s endogenous role remains an “unresolved riddle” with no confirmed receptor or precursor.^[5] When the basic target is unknown, there is no rational basis from which to derive a “correct” dose in the first place. Every figure you see is therefore either a historical research amount or an internet convention — never an established therapeutic dose.

The doses the old human studies actually used

DSIP was given to people at defined doses, but you have to go back to the 1980s to find it, and the details rarely match what’s marketed now. The most-cited human report is a 1984 clinical trial in which patients with severe, often drug-associated insomnia received a series of DSIP injections; the author reported subjective improvement, while being candid about the small numbers and lack of controls.^[1] Separate 1984 pilot work used DSIP intravenously, in the milligram range, under hospital supervision — one study in patients with chronic, pronounced pain episodes,^[2] and another in alcohol and opiate withdrawal.^[3] These were clinic-administered infusions in monitored patients, not before-bed self-injections.

The through-line matters: where DSIP has a dosing history at all, it sits in supervised, intravenous, milligram-scale clinical use from forty years ago — a world away from a microgram subcutaneous shot bought online. The doses don’t even share an order of magnitude or a route of administration.

Why those studies don’t establish a consumer protocol

It is tempting to back-calculate a “dose” from those old papers, but the studies simply can’t bear that weight. They were small, uncontrolled, unblinded, and never replicated in the rigorous placebo-controlled trials that would be needed to call any dose safe or effective.^[1][2][3] They used different routes, different amounts, and different patient populations for different indications. None of them was designed as a dose-finding study, so none answers the only question a protocol needs to answer: how much, how often, for whom, to what measured benefit, at what risk. Extracting a home regimen from a 1984 supervised IV pain pilot is not interpretation — it is invention.

The community ranges — what they are, and aren’t

Step into the forums and a different set of numbers appears: DSIP is typically discussed as a subcutaneous or intranasal dose in the microgram range, often quoted somewhere around 25–100 mcg taken before sleep, a few times a week. It is important to be clear about the status of these figures. They are gray-market convention — passed between users and resellers — not values that descend from the 1984 studies, which used far larger intravenous amounts.^[1][2] No regulator, no controlled study, and no pharmacist has established that range as safe or effective. Treating a “DSIP dosage chart” as guidance mistakes repetition for evidence; it is anecdote dressed as instruction.

The half-life problem: cleared in minutes

There is also a pharmacological reason the simple before-bed-shot model never made obvious sense. DSIP is cleared from the circulation very quickly — metabolic-clearance work measuring administered DSIP found it disappears from plasma on a timescale of minutes, not hours.^[6] A compound that the body removes that fast is hard to dose rationally for an overnight effect, and the early characterization literature treated this short, unstable presence as one of DSIP’s defining and puzzling features.^[7] Combined with the unresolved question of how (or whether) it acts centrally at all,^[5] the half-life data is one more reason no one has been able to build a credible dosing schedule around it.

Reconstitution: arithmetic, not endorsement

DSIP is sold as a lyophilized powder that has to be reconstituted with bacteriostatic water before any injection — and people frequently confuse the mechanics of mixing with the question of what dose is appropriate. They are not the same thing. If you already have a clinician-directed amount and simply need to convert vial milligrams and water volume into a concentration and a syringe reading, our peptide reconstitution calculator does that arithmetic. It is deliberately a math tool, not dosing advice: it tells you how to measure a number you were given, not whether that number is safe or that DSIP should be taken at all.

The honest bottom line

There is no established DSIP dose. The only defined doses in the human record are from a handful of small, uncontrolled 1980s studies that used supervised intravenous, milligram-range administration for insomnia, pain and withdrawal — none of which validates a home regimen.^[1][2][3] The microgram figures online are gray-market convention with no trial, regulator or study behind them, the molecule is cleared from plasma within minutes,^[6] and its fundamental biology remains unresolved.^[5] Treat any “DSIP dosage” chart as anecdote, and treat the decision to use DSIP — and at what dose, if any — as a clinical question, not a forum one. If sleep or recovery is the goal, you’ll find far better-supported options among the peptides that actually carry human dosing data; compare the field in our peptide therapy comparison.